Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Idiopathic Pulmonary Fibrosis

ClinicalTrials.gov lists 574 trials for Idiopathic Pulmonary Fibrosis or a narrower condition beneath it. Boehringer Ingelheim has the most among industry and government lead sponsors, with 35.

MeSH D054990 Respiratory Tract Diseases C08 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 101 Phase 1/2 Phase 1/2 13 Phase 2 Phase 2 135 Phase 2/3 Phase 2/3 4 Phase 3 Phase 3 53 Phase 4 Phase 4 12 Not applicable Not applicable 78 Observational Observational 175 Phase 1 Phase 1 101 Phase 1/2 Phase 1/2 13 Phase 2 Phase 2 135 Phase 2/3 Phase 2/3 4 Phase 3 Phase 3 53 Phase 4 Phase 4 12 Not applicable Not applicable 78 Observational Observational 175

Trials per phase (log scale)

1 more section with rows

566 of the 574 trials are tagged with Idiopathic Pulmonary Fibrosis itself; the rest are tagged with a narrower condition beneath it.

Get the Idiopathic Pulmonary Fibrosis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Idiopathic Pulmonary Fibrosis trials start? (28)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 41

1999: 1 trials (Observational 1) 2000: 3 trials (Phase 3 2, Phase 2 1) 2001: 2 trials (Phase 2 2) 2002: 2 trials (Phase 3 1, Phase 2 1) 2003: 8 trials (Phase 3 2, Phase 2/3 2, Phase 2 2, Phase 1/2 1, Phase 1 1) 2004: 2 trials (Observational 1, Phase 2 1) 2005: 10 trials (Observational 5, Not applicable 2, Phase 3 1, Phase 2 1, Phase 1 1) 2006: 4 trials (Observational 1, Phase 3 2, Phase 1/2 1) 2007: 8 trials (Observational 2, Phase 4 2, Phase 3 3, Phase 2 1) 2008: 10 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 3, Phase 2 3) 2009: 10 trials (Observational 4, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 1) 2010: 13 trials (Observational 5, Not applicable 3, Phase 2 2, Phase 1 3) 2011: 11 trials (Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 7, Phase 1 1) 2012: 19 trials (Observational 7, Not applicable 4, Phase 3 1, Phase 2 5, Phase 1/2 1, Phase 1 1) 2013: 24 trials (Observational 9, Not applicable 3, Phase 3 2, Phase 2 5, Phase 1/2 1, Phase 1 4) 2014: 19 trials (Observational 6, Not applicable 3, Phase 2 6, Phase 1/2 3, Phase 1 1) 2015: 27 trials (Observational 11, Not applicable 3, Phase 4 1, Phase 3 1, Phase 2 5, Phase 1 6) 2016: 26 trials (Observational 11, Not applicable 2, Phase 4 3, Phase 3 2, Phase 2 6, Phase 1 2) 2017: 35 trials (Observational 12, Not applicable 13, Phase 3 2, Phase 2 3, Phase 1/2 1, Phase 1 4) 2018: 41 trials (Observational 18, Not applicable 9, Phase 4 2, Phase 3 2, Phase 2 4, Phase 1/2 1, Phase 1 5) 2019: 29 trials (Observational 13, Not applicable 5, Phase 3 1, Phase 2 4, Phase 1 6) 2020: 36 trials (Observational 12, Not applicable 3, Phase 4 1, Phase 3 4, Phase 2 9, Phase 1/2 1, Phase 1 6) 2021: 34 trials (Observational 9, Not applicable 3, Phase 3 4, Phase 2 3, Phase 1/2 1, Phase 1 14) 2022: 41 trials (Observational 11, Not applicable 5, Phase 3 3, Phase 2 12, Phase 1/2 1, Phase 1 9) 2023: 39 trials (Observational 5, Not applicable 5, Phase 3 2, Phase 2/3 1, Phase 2 12, Phase 1/2 1, Phase 1 13) 2024: 34 trials (Observational 10, Not applicable 2, Phase 3 1, Phase 2 10, Phase 1 11) 2025: 33 trials (Observational 10, Not applicable 3, Phase 3 2, Phase 2 13, Phase 1 5)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 47
2025 33
2024 34
2023 39
2022 41
2021 34
2020 36
2019 29
2018 41
2017 35

Showing 10 of 28 earlier years.

Start your 14-day trial Email me all 28 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 56 trials starting in 2026 and about 43 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 34 months from start to primary completion across 56 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 360 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Idiopathic Pulmonary Fibrosis trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 101
Phase 1/2 13
Phase 2 135
Phase 2/3 4
Phase 3 53
Phase 4 12
Not applicable 78
Observational 175
Expanded access 3

How many Idiopathic Pulmonary Fibrosis trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 28
Recruiting 74
Enrolling by invitation 4
Active, not recruiting 31
Completed 307

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Idiopathic Pulmonary Fibrosis trials? (9)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Boehringer Ingelheim 35
Hoffmann-La Roche 16
Bristol-Myers Squibb 9
Genentech, Inc. 7
GlaxoSmithKline 7

Showing 5 of 9 sponsors.

Start your 14-day trial Email me all 9 sponsors as a PDF

Which drugs are being tested for Idiopathic Pulmonary Fibrosis? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
SILDENAFIL 8
BMS 986278 6
BI 1015550 5
FG-3019 5
BOSENTAN 5

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Pirfenidoneone 39
L01XE31 - Nintedanib 31
Gamma Interferon 1b 6
HEC585 6
PLN-74809 4

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Idiopathic Pulmonary Fibrosis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Idiopathic pulmonary fibrosis 2,484 55
Pneumonia 1,016 58
Respiratory failure 412 43
Dyspnoea 347 41
Pneumothorax 327 35

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Idiopathic Pulmonary Fibrosis? (484)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Zone of z-scores uncertainty in pulmonary function interpretation: A proof-of-concept study from CO and NO lung diffusing capacities. Respiratory medicine 2026 Yes
Comprehensive characterisation of individuals with fibrotic interstitial lung disease: baseline insights from the INJUSTIS study. BMJ open respiratory research 2026 Yes
Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON). BMC pulmonary medicine 2025 Yes
Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab. BMJ open 2025 Yes
Efficacy and Safety of Admilparant, an LPA<sub>1</sub> Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. American journal of respiratory and critical care medicine 2025 Yes

Showing 5 of 484 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (51)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Idiopathic pulmonary fibrosis Point prevalence 1-5 / 10 000 United Kingdom GB Unspecified
Idiopathic pulmonary fibrosis Annual incidence 1-9 / 100 000 United Kingdom GB Exact
Idiopathic pulmonary fibrosis Point prevalence 1-5 / 10 000 United Kingdom GB Exact
Idiopathic pulmonary fibrosis Annual incidence 1-9 / 100 000 United Kingdom GB Unspecified
Idiopathic pulmonary fibrosis Point prevalence 1-5 / 10 000 United Kingdom GB Exact

Showing 5 of 51 prevalence observations.

Start your 14-day trial Email me the first 50 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Idiopathic pulmonary fibrosis 2032 Exact Orphanet Rare Disease Ontology (ORDO)
Idiopathic pulmonary fibrosis 2032 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages